- Home
- AMPX vs KOD Comparison
AMPX vs KOD Comparison
Compare AMPX & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPX
- KOD
- Stock Information
- Founded
- AMPX 2008
- KOD 2009
- Country
- AMPX United States
- KOD United States
- Employees
- AMPX N/A
- KOD N/A
- Industry
- AMPX Industrial Machinery/Components
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMPX Miscellaneous
- KOD Health Care
- Exchange
- AMPX Nasdaq
- KOD Nasdaq
- Market Cap
- AMPX 126.6M
- KOD 121.5M
- IPO Year
- AMPX N/A
- KOD 2018
- Fundamental
- Price
- AMPX $1.22
- KOD $2.66
- Analyst Decision
- AMPX Strong Buy
- KOD Hold
- Analyst Count
- AMPX 7
- KOD 5
- Target Price
- AMPX $8.17
- KOD $3.25
- AVG Volume (30 Days)
- AMPX 1.3M
- KOD 162.1K
- Earning Date
- AMPX 11-07-2024
- KOD 11-12-2024
- Dividend Yield
- AMPX N/A
- KOD N/A
- EPS Growth
- AMPX N/A
- KOD N/A
- EPS
- AMPX N/A
- KOD N/A
- Revenue
- AMPX $12,423,000.00
- KOD N/A
- Revenue This Year
- AMPX $66.77
- KOD N/A
- Revenue Next Year
- AMPX $311.17
- KOD N/A
- P/E Ratio
- AMPX N/A
- KOD N/A
- Revenue Growth
- AMPX 216.99
- KOD N/A
- 52 Week Low
- AMPX $0.61
- KOD $1.37
- 52 Week High
- AMPX $6.02
- KOD $7.77
- Technical
- Relative Strength Index (RSI)
- AMPX 61.12
- KOD 52.94
- Support Level
- AMPX $0.97
- KOD $2.50
- Resistance Level
- AMPX $1.13
- KOD $2.80
- Average True Range (ATR)
- AMPX 0.14
- KOD 0.18
- MACD
- AMPX 0.03
- KOD 0.01
- Stochastic Oscillator
- AMPX 75.93
- KOD 64.71
About AMPX Amprius Technologies Inc.
Amprius Technologies Inc is engaged in the production of silicon anodes for high energy density lithium-ion batteries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. All of its revenues is geographically earned in the United States.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.